Cryoport Systems is repositioning the conversation around supply chains for advanced therapies, arguing that quality must be embedded from the ground up rather than applied as an afterthought.
Adam Fox, Chief Quality and Regulatory Affairs Officer of Cryoport Systems, has outlined how escalating regulatory expectations are fundamentally reshaping the design and scaling of advanced therapy supply chains.
Fox made his remarks during a Dedicated Dialogue episode, a format focused on in-depth industry conversations exploring the most pressing operational and compliance challenges facing modern therapeutics.
His central argument is that traditional supply chain models are structurally ill-equipped to handle the demands of cell and gene therapy, which require far greater precision and control than conventional pharmaceutical products.
The stakes are exceptionally high in this space, where temperature-controlled materials carry enormous patient value and any failure in the distribution chain can have direct and serious consequences for outcomes.
Fox examined the quality infrastructure and end-to-end control strategies that organisations must adopt to adequately protect these high-value biological materials throughout their journey from manufacturer to patient.
Regulatory bodies around the world are intensifying their scrutiny of advanced therapy supply chains, placing greater pressure on manufacturers and logistics partners to demonstrate robust, auditable quality systems.
Patient-centric risk considerations are also driving this shift, with the recognition that a compromised cell or gene therapy product cannot simply be replaced in the way a conventional medicine might be.
Cryoport Systems positions itself as a partner capable of helping organisations maintain both compliance and operational continuity across what Fox describes as the world’s most complex distribution networks.
The company’s approach centres on what Fox calls a quality-driven playbook, designed to give therapeutic developers a structured framework for managing risk across every node of the supply chain.
Leading organisations in the advanced therapy space are increasingly recognising that quality cannot be a downstream consideration but must instead form the foundation of supply chain strategy from the earliest stages of development.
As cell and gene therapies continue to move from clinical trials into commercial-stage products, the pressure to scale quality systems without sacrificing control or compliance will only intensify across the sector.
Cryoport Systems argues that its infrastructure and expertise place it in a strong position to support that transition for developers navigating an increasingly demanding global regulatory landscape.